Change in cardiovascular risk scores from baseline to week 24 with data censored at rescue
| RA-BEAM | RA-BUILD | RA-BEACON | |||||||
| Placebo (n=488) | Baricitinib 4 mg (n=487) | Adalimumab (n=330) | Placebo (n=228) | Baricitinib 2 mg (n=229) | Baricitinib 4 mg (n=227) | Placebo (n=126) | Baricitinib 2 mg (n=127) | Baricitinib 4 mg (n=137) | |
| Framingham Risk Score | |||||||||
| Baseline | 9.9 (9.9) | 8.8 (9.6) | 9.6 (10.0) | 7.7 (6.8) | 7.6 (6.4) | 7.5 (6.6) | 8.5 (6.3) | 8.0 (6.4) | 8.2 (8.0) |
| Change from baseline to week 24 | 0.02 (0.19) | 0.28 (0.17) | −0.07 (0.21) | −0.30 (0.25) | 0.02 (0.22) | −0.01 (0.22) | −0.24 (0.39) | −0.46 (0.34) | 0.63 (0.32) |
| Reynolds Risk Score | |||||||||
| Baseline | 5.4 (6.7) | 4.5 (4.6) | 5.3 (6.1) | 4.7 (5.0) | 3.9 (3.6) | 4.4 (4.2) | 5.1 (5.8) | 4.3 (4.5) | 4.6 (4.1) |
| Change from baseline to week 24 | −0.11 (0.16) | −0.98 (0.15)*† | −1.08 (0.18)*† | −0.59 (0.20)‡ | −0.66 (0.17)* | −0.47 (0.17)† | −0.32 (0.29) | −0.74 (0.26)‡ | −0.69 (0.26)‡ |
Baseline are mean (SD).
Change from baseline data are least squares mean (SE).
*Significant within-group change from baseline (P<0.001).
†Significant change from baseline versus placebo (P<0.001).
‡Significant within-group change from baseline (P<0.01).
RA, rheumatoid arthritis.